Sometimes, Clinical Trials Miss the Mark: Neurocrine, Akebia, Eliem and Athira

In keeping with the statistic that only about one drug in 10 makes it to regulatory approval, this week has seen several clinical trial failures. Here’s an in-depth look at a few of them.